N-acetylcysteine for newborn sepsis: a study
Treatments studied
Part of Genetic & congenital, Infections clinical trials.
This study tests whether adding N-acetylcysteine (NAC) to standard care helps newborns with sepsis recover better. It is for babies born at 32 weeks or later, within the first 28 days of life, who have a confirmed infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be born at or after 32 weeks of pregnancy and be less than 28 days old.
- Your baby must have been diagnosed with sepsis (a serious infection in the blood).
- Your baby cannot have life-threatening birth defects that would prevent them from living through the first 28 days.
- Your baby must not be allergic to N-acetylcysteine (NAC).
- You, as a parent or guardian, must agree to let your baby join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new blood test (called presepsin) to see if it can help doctors quickly diagnose sepsis (a serious infection) in newborns. If your baby has signs of infection, this test might help find the cause sooner.
This study looks at how blood markers like lactate and complete blood count (CBC) can help spot infection in newborns up to 28 days old. It may lead to faster, more accurate diagnosis for babies with possible sepsis.
This study tests if a special hand-cleaning method using chlorhexidine and alcohol can help prevent infections in premature babies (born before 37 weeks) in the newborn intensive care unit (NICU). It aims to see if this cleaning approach is better than the usual method for keeping babies safe from hospital-acquired infections.
This trial tests if methylene blue given through an IV can help newborns with severe septic shock that isn't getting better with standard treatments like fluids and blood pressure medicines.
This trial tests if N-acetylcysteine, a medicine that helps the liver and fights inflammation, can improve outcomes for adults with a severe infection and liver stress.
This trial is testing ways to make the best treatment decisions for newborns who may have an early infection (sepsis). It focuses on babies born at 34 weeks or later and within their first three days of life.
Hear when a new Neonatal Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.